Back to Biosimilars in Present Tense: Applying the Science to Hematology/Oncology Pharmacy Practice
Biosimilars in Present Tense: Applying the Science to Hematology/Oncology Pharmacy Practice

Biosimilars in Present Tense: Applying the Science to Hematology/Oncology Pharmacy Practice

Activity Title

Biosimilars in Present Tense: Applying the Science to Hematology/Oncology Pharmacy Practice

Recorded at a live CSS during the HOPA Practice Management Program

Topic

Biosimilars

Accreditation Type

ACPE pharmacy credit

Release Date

10/31/18

Expiration Date

10/30/19

Estimated Time to Complete Activity

45-minutes

Product Details

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Describe biosimilars, follow-on biologics, interchangeability, and extrapolation of indications on the basis of FDA definitions and guidance
  • Explain key aspects of current FDA guidance/processes that inform the pharmacist’s knowledge of the biosimilar approval process, manufacturing, lack of bioequivalence, labeling, and naming, as well as state regulations surrounding substitution
  • Discuss the potential implications of switching between biologics and biosimilars, or between biosimilars
  • Identify reliable resources on biologics and biosimilars, such as the FDA’s Purple Book and online educational tools
  • Apply knowledge on biosimilars to clinical, as well as health-system/committee (e.g., formulary) and patient education situations, related to pharmacy practice

 

Faculty

Adam Brufsky, MD, PhD

Professor of Medicine

Associate Chief, Division of Hematology-Oncology

University of Pittsburgh School of Medicine

Pittsburgh, PA

 

Ali McBride PharmD, MS, BCOP, FAzPA, FASHP

Clinical Coordinator Hematology/Oncology

The University of Arizona Cancer Center

Clinical Assistant Professor

College of Pharmacy

The University of Arizona

Tucson, AZ

 

Rowena Schwartz, PharmD, BCOP

Associate Professor of Pharmacy Practice

University of Cincinnati

Cincinnati, OH

  • List Price: Free